BioMarin Seeks Traditional FDA Approval for VOXZOGO as a Weekly Option Enters the Field

원문 링크: WordPress 원문

ENGKOR

VOXZOGO (vosoritide) is BioMarin’s once-daily subcutaneous CNP-analog treatment for children with achondroplasia whose growth plates are still open. Achondroplasia commonly involves an activating FGFR3 variant that restrains endochondral bone growth; vosoritide activates natriuretic peptide receptor B to counter signaling downstream of that overactivity.[2]

The FDA first granted VOXZOGO accelerated approval in 2021, based on an improvement in annualized growth velocity. In plain language, it is an already available daily treatment whose longer-term clinical benefit still needs confirmation—not a newly introduced medicine.[2]

This article is about the next regulatory question. On 13 July 2026, BioMarin announced FDA acceptance of a supplemental application seeking to convert VOXZOGO’s accelerated approval to traditional approval. The target action date is 28 February 2027; acceptance starts a review, but does not mean that traditional approval has already been granted.[1]

The field also has a newer weekly option. In early 2026, FDA granted accelerated approval to once-weekly CNP analog YUVIWEL (navepegritide) for children aged 2 years and older with open epiphyses.[5,6] VOXZOGO is daily; YUVIWEL is weekly. Frequency alone cannot determine better long-term outcomes.

If you remember only four things

• The FDA accepted a review application; it did not approve the conversion yet.

• VOXZOGO’s current US indication remains under accelerated approval and is based on improvement in annualized growth velocity.[2]

• BioMarin says its sNDA includes longer-term outcomes such as adult height, body proportionality, and arm span, but the detailed confirmatory results have not yet been disclosed publicly in a complete peer-reviewed report.[1,8]

• YUVIWEL adds a once-weekly option, but there is no head-to-head evidence here establishing clinical superiority over VOXZOGO.

What accelerated approval meant for VOXZOGO

Achondroplasia is usually caused by an activating FGFR3 variant that restrains endochondral bone growth. Vosoritide activates natriuretic peptide receptor B to counter signaling downstream of overactive FGFR3.[2]

The FDA first granted VOXZOGO accelerated approval in 2021. Its current label covers pediatric patients with achondroplasia who have open epiphyses, without a minimum age, and directs once-daily subcutaneous dosing based on body weight.[2]

Accelerated approval can rely on an endpoint reasonably likely to predict clinical benefit, with later verification required. For VOXZOGO, that endpoint was annualized growth velocity.

In the pivotal 52-week randomized trial, 121 children aged 5 to under 18 years received daily vosoritide or placebo. The adjusted between-group difference in annualized growth velocity was 1.57 cm per year in favor of vosoritide.[3] The study supported an effect on short-term linear growth. It did not, at that time, establish final adult height or resolve the broader question of how treatment changes function, complications, quality of life, or body proportionality over many years.

What BioMarin says is in the new package

According to BioMarin, the sNDA draws on long-term safety and efficacy follow-up from studies 111-205, 111-208, and 111-302. These correspond to ClinicalTrials.gov records NCT02724228, NCT03989947, and NCT03424018.[1,4]

The company says the package includes adult-height outcomes and skeletal measures beyond annualized growth velocity, including body proportionality and arm span. These are more directly connected to the regulatory question than another one-year growth-velocity result would be. But a list of endpoints is not the same thing as seeing the data.

The public announcement does not show participant numbers for mature adult-height analyses, completeness of follow-up, missing-data handling, or effect sizes. Long-term extension cohorts also differ from a new randomized comparison because those who continue may not represent everyone who started.

The safest interpretation is therefore narrow: BioMarin has submitted a confirmatory package intended to support conversion, and the FDA is reviewing it. Whether the package verifies clinical benefit will be decided through the review process.

Conceptual illustration

Conceptual illustration of the evidence pathway. It does not depict an individual child, a commercial device, or an FDA conclusion.

What traditional approval could change—and what it would not

If the FDA grants traditional approval, the regulatory basis of the indication would no longer depend on continued verification under the accelerated-approval pathway. That would be a meaningful milestone for BioMarin and for the achondroplasia field.

It would not prove that treatment prevents every complication or is superior to another therapy. Individual discussion of treatment goals, injection burden, adverse effects, growth potential, and family values would remain essential.

The current label warns of transient blood-pressure decreases. Patients should eat and drink adequately before dosing, and treatment stops when epiphyses close.[2] Common adverse reactions include injection-site reactions, vomiting, rash, arthralgia, decreased blood pressure, and gastroenteritis.[2]

The weekly option: a different schedule, another accelerated approval

YUVIWEL entered the US market through the same broad regulatory route: accelerated approval based on improved annualized growth velocity. Its label covers children aged 2 years and older with achondroplasia and open epiphyses and specifies once-weekly subcutaneous administration.[6,7]

The FDA reports that the pivotal trial enrolled 84 treatment-naïve children. At 52 weeks, children assigned to YUVIWEL grew an average of 1.5 cm more than those assigned to placebo. The study then continued into an open-label extension, and the FDA states that the second-year growth rate was maintained among those treated for two years.[5]

Those numbers should not be placed directly beside VOXZOGO’s 1.57 cm/year result and treated as a ranking. The trials enrolled different populations, used different randomization ratios and analysis plans, and were conducted in different programs. Only a well-designed head-to-head comparison could support a direct efficacy claim.

The schedule difference may affect family routines and injection experience, but convenience is not clinical superiority. YUVIWEL requires reconstitution, uses weight-based dosing, and carries a low-blood-pressure warning; some weight bands require two injections for a weekly dose.[6]

Why another option could still matter

The second CNP analog adds questions about treatment age, schedule, preparation, safety experience, long-term evidence, access, insurance coverage, and outcomes important to each family.

This should not be reduced to a contest over centimeters. Achondroplasia is a lifelong skeletal dysplasia with health, functional, and social dimensions. Height is measurable, but patient-relevant evaluation can also include proportionality, mobility, pain, daily function, procedures, sleep-disordered breathing, neurologic complications, and quality of life. Not every endpoint will be affected by a CNP analog, and not every family will value the same trade-offs.

Multiple options can encourage better follow-up and reporting, but separate trials should not be treated as one experiment.

What to watch before 28 February 2027

• Whether BioMarin publishes the mature adult-height and proportionality data in enough detail for independent assessment

• How many participants contribute to each long-term outcome and how missing follow-up is handled

• Whether the FDA accepts the proposed endpoints as verification of clinical benefit

• Any label changes to population, safety language, or postmarketing commitments

• Real-world evidence on daily and weekly administration, including persistence and treatment burden

• Whether comparative trials are planned rather than inferred from separate placebo-controlled studies

Bottom line

VOXZOGO is under FDA review for conversion to traditional approval, not already converted. The sNDA appears designed to answer the central confirmatory question left by accelerated approval: whether a short-term gain in growth velocity translates into durable, clinically meaningful skeletal outcomes. Meanwhile, YUVIWEL has introduced a weekly schedule under its own accelerated approval.

The field should be judged by transparent long-term evidence, patient-relevant outcomes, safety, and meaningful choices—not headline convenience or isolated centimeter figures.

This article is educational commentary based on public regulatory and clinical sources. It is not medical advice, treatment guidance, investment advice, or a recommendation of any company, medicine, or security.

References

• BioMarin announcement: FDA accepts sNDA for full approval of VOXZOGO (13 July 2026) — application status, PDUFA date, and company description of the long-term package

• VOXZOGO Prescribing Information, revised November 2024 — current US indication, accelerated-approval language, dosing, and safety

• Savarirayan et al. Once-daily vosoritide therapy in children with achondroplasia. The Lancet 2020 — randomized phase 3 trial

• ClinicalTrials.gov: NCT02724228 , NCT03989947 , and NCT03424018 — study records corresponding to 111-205, 111-208, and 111-302

• FDA: Yuviwel approval summary — approval basis, study population, and 52-week result

• YUVIWEL Prescribing Information, approved February 2026 — indication, weekly dosing, administration, and safety

• ClinicalTrials.gov: NCT05598320 — pivotal YUVIWEL study record

• Contemporary Pediatrics: FDA accepts sNDA for vosoritide (13 July 2026) — independent clinical-news context and public-data limitations